TZ9 is a selective Rad6 inhibitor. TZ9 inhibits Rad6B-induced histone H2A ubiquitination, downregulates intracellular β-catenin, induces G2-M arrest and Apoptosis, and inhibits the proliferation and migration of metastatic human breast cancer cells[1].
体外研究 (In Vitro)
TZ9 (Rad6B SMI #9) (0.5-100 µM; 72 h) inhibits MDA-MB-231 cell proliferation and migration[1]. TZ9 (0.1-5 µM; 24-72 h) delays cell-cycle progression in MDA-MB-231 cells[1]. TZ9 (5 µM; 8-48 h) induces apoptosis in MDA-MB-231 cells[1]. TZ9 (0.5, 1, 2.5, 5 µM; 24 h) inhibits H2A ubiquitination and downregulates levels of PCNA and β-catenin protein in MDA-MB-231 cells[1].
MCE has not independently confirmed the accuracy of these methods. They are for reference only.